• 1. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Research Brief on 2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid (CAS: 1260658-97-6) in Chemical Biology and Pharmaceutical Applications

2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid (CAS: 1260658-97-6) is a pyrazole derivative that has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This compound, characterized by its unique structural features, has been explored as a key intermediate in the synthesis of bioactive molecules and as a potential pharmacophore in medicinal chemistry. Recent studies have highlighted its role in modulating various biological targets, making it a promising candidate for further investigation.

Recent literature indicates that this compound has been utilized in the development of small-molecule inhibitors targeting inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a building block for synthesizing novel COX-2 inhibitors with improved selectivity profiles. The isopropyl-substituted pyrazole moiety was found to contribute significantly to the binding affinity and metabolic stability of the resulting compounds, suggesting potential applications in anti-inflammatory drug development.

In the field of oncology research, 2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid has shown promise as a scaffold for kinase inhibitor design. A recent patent application (WO2023056789) disclosed its incorporation into ATP-competitive inhibitors targeting the PI3K/AKT/mTOR pathway, with demonstrated activity against various cancer cell lines. The compound's structural flexibility allows for modifications that can fine-tune selectivity and pharmacokinetic properties, addressing some of the challenges in kinase inhibitor development.

From a synthetic chemistry perspective, novel methodologies for the efficient preparation of this compound have been reported. A 2024 publication in Organic Process Research & Development described an improved synthetic route featuring a one-pot cyclization and alkylation process, achieving higher yields (78%) compared to traditional methods. This advancement is particularly relevant for scaling up production while maintaining cost-effectiveness, an important consideration for pharmaceutical applications.

Emerging research has also explored the compound's potential in central nervous system (CNS) drug discovery. Computational modeling studies suggest that derivatives of 2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid may exhibit favorable blood-brain barrier penetration properties, making them interesting candidates for neurological disorder treatments. Preliminary in vivo studies in rodent models have shown promising results in modulating GABAergic neurotransmission, though further validation is required.

The compound's physicochemical properties, including its moderate lipophilicity (logP ~2.1) and good aqueous solubility (12 mg/mL at pH 7.4), contribute to its drug-like characteristics. Recent ADMET profiling studies have indicated acceptable metabolic stability in human liver microsomes (t1/2 > 60 minutes) and low cytochrome P450 inhibition potential, supporting its utility as a lead compound in medicinal chemistry programs.

Future research directions for 2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid appear to focus on three main areas: (1) development of targeted covalent inhibitors leveraging its reactive carboxyl group, (2) exploration of its metal-chelating properties for metalloenzyme inhibition, and (3) investigation of its potential as a bioisostere for carboxylic acid-containing natural products. These diverse applications underscore the compound's versatility and continued relevance in pharmaceutical research.

• 177940-21-5(2-[1-(propan-2-yl)-1H-pyrazol-3-yl]ethan-1-ol)
• 1357353-48-0(2-(1-methyl-1H-pyrazol-3-yl)acetic acid hydrochloride)
• 1342027-45-5(1-1-(propan-2-yl)-1H-pyrazol-3-ylpropan-2-one)
• 1909313-60-5(2-(1-ethyl-1H-pyrazol-3-yl)acetic acid hydrochloride)
• 2126176-85-8(2-[1-(Propan-2-yl)-1H-pyrazol-3-yl]acetic acid hydrochloride)
• 1260659-07-1(2-(1-Cyclopentyl-1H-pyrazol-3-yl)acetic acid)
• 1260659-31-1(2-(1-ethyl-1H-pyrazol-5-yl)acetic acid)
• 1006483-09-5(3-(1-ethyl-1H-pyrazol-3-yl)propanoic acid)
• 1172566-04-9(2-(1-ethyl-1H-pyrazol-3-yl)acetic acid)
• 1177318-00-1(2-(1-methylpyrazol-3-yl)acetic acid)